Ranibizumab Treatment for Retinal Vein Occlusion

Kyoto University, Graduate School of Medicine

Status: Unknown

Conditions: Macular Edema Due to BRVO/CRVO

Treatments: Drug: Ranibizumab, 0.5mg, Intravitreal

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01968616

KY-RV-R

Details and patient eligibility

About

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent form
• Male or female of aged 18 years or older
• Macula edema secondary to BRVO/CRVO
• Decrease of VA due to macular edema

Exclusion criteria

• Prior episode of RVO
• Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)
• Ocular disorders in the study eye that may confound interpretation of study results
• History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO
• The pregnant or lactating woman

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Intravitreal Lucentis 0.5mg

Other group

Description:

One arm

Treatment:

Drug: Ranibizumab, 0.5mg, Intravitreal